Efficacy and long‐term patency of fenestrated amplatzer devices in children

10 children (5 male, age 1.5-15.5 years) requiring control of interatrial communications (7 with severe symptomatic pulmonary hypertension, 2 with large atrial septal defects and associated pulmonary hypertension, 1 requiring left atrial offloading prior to heart transplantation).

Implantation of fenestrated atrial septal devices (6 modified by manufacturer, 4 modified by operator) with antithrombotic therapy (warfarin n=5, aspirin n=4, or heparin n=1).

Symptom improvement and device patency on echocardiographysurrogate